These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7587028)

  • 1. Retrospective analysis of the clinical and economic outcomes of twice-daily dosing of cefotaxime in a Canadian tertiary care institution.
    Tin LY; Pitre M; Conly JM
    Diagn Microbiol Infect Dis; 1995; 22(1-2):135-40. PubMed ID: 7587028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective analysis of twice-daily cefotaxime compared to conventional therapy for the treatment of infections in a USA hospital.
    Burke JP; Pestotnik SL; Classen DC; Lloyd JF
    Diagn Microbiol Infect Dis; 1995; 22(1-2):167-9. PubMed ID: 7587034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of the efficacy of cefotaxime sodium dosed twice daily. The Swedish experience.
    Bergquist SO; Eriksson I; Eriksson S; Lönnbro N; Runehagen A; Styrud J; Ahlquist G
    Diagn Microbiol Infect Dis; 1995; 22(1-2):163-6. PubMed ID: 7587033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections.
    Simmons BP; Gelfand MS; Grogan J; Craft B
    Diagn Microbiol Infect Dis; 1995; 22(1-2):155-7. PubMed ID: 7587031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review and reassessment of dosing schedules for cefotaxime in selected medical indications.
    Young LS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):147-54. PubMed ID: 7587030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of cefotaxime twice daily for the therapy of postoperative pneumonia. The German Cefotaxime Study Group.
    Bruch HP; Kujath P
    Diagn Microbiol Infect Dis; 1995; 22(1-2):203-7. PubMed ID: 7587041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of twice-daily cefotaxime in the treatment of hospitalized patients with severe infections.
    Keller C
    Diagn Microbiol Infect Dis; 1995; 22(1-2):159-61. PubMed ID: 7587032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM
    Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.
    Hitt CM; Nightingale CH; Quintiliani R; Nicolau DP
    Am J Health Syst Pharm; 1997 Jul; 54(14):1614-8. PubMed ID: 9248605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia. Results of a multicenter study.
    Shah PM; Stille W
    Diagn Microbiol Infect Dis; 1995; 22(1-2):171-2. PubMed ID: 7587035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime and metronidazole in severe intra-abdominal infection.
    Aprahamian C; Schein M; Wittmann D
    Diagn Microbiol Infect Dis; 1995; 22(1-2):183-8. PubMed ID: 7587037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK; Ostergaard BE; Rotschafer JC
    Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pharmacological evaluation of a modified cefotaxime bid regimen versus traditional tid in pediatric lower respiratory tract infections.
    Boccazzi A; Tonelli P; Bellosta C; Careddu P
    Diagn Microbiol Infect Dis; 1998 Dec; 32(4):265-72. PubMed ID: 9934543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
    Wessels F; Anderson AN; Ebrahim O
    S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefotaxime use in pediatric infections.
    Dajani AS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):105-10. PubMed ID: 7587022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefotaxime and ceftriaxone use evaluation in pediatrics. Considerations of cost effectiveness.
    Lee CK; Glenn DJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):231-3. PubMed ID: 7587045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the clinical features of cefixime.
    Adam D
    Chemotherapy; 1998 Sep; 44 Suppl 1():1-5. PubMed ID: 9797415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of cefotaxime on patients admitted to the internal medicine service of a general hospital. An analysis from the viewpoint of health economics].
    Moreno Palomares JJ; Fernández Ordóñez R; Reverte Cejudo D
    An Med Interna; 1997 Apr; 14(4):174-8. PubMed ID: 9181812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.